Cases
Ampio Pharmaceuticals, Inc. (AMPE)
Securities Class Action
Overview
Overview
- Date:
- 10/26/2018
- Company Name:
- Ampio Pharmaceuticals, Inc.
- Stock Symbol:
- AMPE
- Class Period:
- FROM 12/14/2017 TO 8/7/2018
- Status:
- Closed/Complete
NEW YORK, October 26, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Ampio Pharmaceuticals, Inc. (NYSE: AMPE).
On August 25, 2018, a complaint was filed alleging that between December 14, 2017 and August 7, 2018, defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampion; (3) consequently, defendants’ public statements were materially false and misleading at all relevant times.
If you are a long term stockholder of Ampio, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.
On August 25, 2018, a complaint was filed alleging that between December 14, 2017 and August 7, 2018, defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampion; (3) consequently, defendants’ public statements were materially false and misleading at all relevant times.
If you are a long term stockholder of Ampio, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.